Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Ahn on the Increased Understanding of Cholangiocarcinoma

October 8th 2021

Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.

Onvansertib Combination Aims to Improve Poor Prognosis in PDAC

October 7th 2021

Patients with pancreatic ductal adenocarcinoma experience limited benefit with available first- and second-line second line of therapy.

Triplet Combo Produces Promising Preliminary Activity in BRAF V600E–Mutant Metastatic CRC

October 5th 2021

The triplet combination comprised of encorafenib, binimetinib, and cetuximab elicited encouraging responses with a manageable safety profile in patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer, meeting the primary end point of the phase 2 ANCHOR-CRC trial.

New Sequencing Strategies Could Hold Key to Improved Outcomes Across GI Malignancies

October 3rd 2021

Heloisa P. Soares, MD, PhD, discusses recent developments in NETS, pancreatic cancer, and GEJ tumors, as well as sequencing strategies aimed at improving patient outcomes across GI cancers.

Dr. Sia on a Novel Classification System in Intrahepatic Cholangiocarcinoma

October 1st 2021

Daniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.

Optimizing Precision Medicine in HCC

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

FDA Grants Fast Track Status to NUC-1031 for Biliary Tract Cancer

September 29th 2021

The FDA has granted a fast track designation to the first-in-class nucleotide analogue NUC-1031 for use as a potential therapeutic option in the frontline treatment of patients with advanced biliary tract cancer.

Infigratinib Approved in Canada for FGFR2+ Cholangiocarcinoma

September 29th 2021

Health Canada has approved infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.

Dr. Harris on Remaining Questions With Treatment Sequencing in HCC

September 27th 2021

William P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.

Pembrolizumab Plus BSC Improves OS in Advanced HCC Previously Treated With Sorafenib

September 27th 2021

The addition of pembrolizumab to best supportive care resulted in a statistically significant improvement in overall survival vs BSC alone in Asian patients with advanced hepatocellular carcinoma who previously received treatment with sorafenib, meeting the primary end point of the phase 3 KEYNOTE-394 trial.

FDA Approval Sought for Frontline Nivolumab Plus Ipilimumab or Chemo in Advanced ESCC

September 27th 2021

The FDA has accepted the supplemental biologics license applications for nivolumab plus ipilimumab and nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy in the frontline treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Janjigian Spotlights Significance of Nivolumab/Chemo Approval for Frontline Gastric Cancer

September 24th 2021

Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.

Second-Line Treatment Approaches for Advanced HCC

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

Fixed-Dose Eniluracil Under Investigation in Advanced Refractory Gastrointestinal Cancers

September 23rd 2021

Fixed-dose eniluracil is being evaluated with escalating doses of capecitabine in patients with advanced, refractory gastrointestinal cancers, or in advanced GI cancers who are intolerant to fluoropyrimidine chemotherapy, as part of an open-label, phase 1b dose-escalation trial.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Cabozantinib Demonstrates Real-World OS Benefit in Second-Line RCC

September 18th 2021

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Trastuzumab Deruxtecan Elicits Encouraging Activity in Western Patients With HER2+ Gastric/GEJ Cancer

September 17th 2021

Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate in Western patients with HER2-positive gastric/gastroesophageal junction cancer.